Moteur de recherche d’entreprises européennes
Financement de l’UE (6 864 579 €) : Patch de diagnostic in vitro microfluidique décentralisé pour le contrôle de la pandémie Hor 01/01/2024 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
Patch de diagnostic in vitro microfluidique décentralisé pour le contrôle de la pandémie
In vitro diagnostic (IVD) technologies have revolutionized healthcare, yet remain confined to the laboratories. This traditional approach massively failed to manage viral outbreak during the COVID-19 pandemic because it lacked quick and cost-effective diagnosis. Moreover, an urgent need was evident for bringing quantitative lab-quality diagnosis to the hands of end users (i.e., point-of-care, POC). Despite high expectations from Lab-on-Chip technologies, they failed so far to disrupt the IVD market due to their complexity, high cost, off-chip sample preparation, poor scalability, to mention a few. The DECIPHER consortium aims to revolutionize the POC IVD field by developing innovative microfluidic-based DECIPHER patch capable of both biofluids (self-)sampling via hollow microneedles (HMNs) and immediate analysis of this sample on the very same patch in a completely self-powered manner, producing quantitative result to be read out with a re-purposed glucose meter. Ebola and Lassa viruses are selected as relevant model systems because they are highly contagious with human-to-human transmission, high mortality rate and no vaccine/treatment available, thus having meaningful potential for new pandemic threats. To offer such a genuine sample-to-result quantitative POC solution, the DECIPHER value chain, from lab to market, will cover: (1) investigation of high-throughput manufacturing processes with (2) novel polymers, innovations in the fields of (3) microfluidics, (4) HMNs and (5) quantitative molecular bioassays, (6) DECIPHER patch analytical and clinical validation (both retrospective and prospective), as well as (7) AI-based models, (8) socio-economic/systems analysis and (9) life cycle assessment of DECIPHER patch. This true interdisciplinarity will be represented by highly experienced DECIPHER consortium with partners from 3 universities, 5 research institutes, 1 SME, 1 large company and 1 non-governmental organization from 6 countries.
| Médecins Sans Frontières Belgium | ? |
| Carnegie Mellon University | 718 540 € |
| Centre National DE Formation ET DE Recherche EN Sante Rurale DE Maferinyah | 207 761 € |
| Epcon B.V. | 280 109 € |
| Institut National DE Recherche Biomedicale Du Zaire | 120 000 € |
| Instituut Voor Tropische Geneeskunde | 1 075 068 € |
| Joanneum Research Forschungsgesellschaft mbH | 953 136 € |
| Katholieke Universiteit Leuven | 2 445 328 € |
| Montanuniversitaet Leoben | 416 024 € |
| Polymer Competence Center Leoben GmbH | 487 596 € |
| Temicon GmbH | 161 018 € |
https://cordis.europa.eu/project/id/101137242
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Médecins Sans Frontières Belgium, Bruxelles, Belgique.